Bennie 1995.

Methods	Six‐week double‐blind, randomised multicentre study
Participants	Outpatients with a diagnosis of major depression or bipolar disorder, depressed, according to DSM‐III‐R, scoring at least 18 on the Hamilton Rating Scale for Depression‐17 item (HDRS‐17), and with a higher on the Raskin Depression Scale than on the Covi Anxiety Scale. Age: over 18 years Exclusion criteria: pregnant or lactating women, women of childbearing potential not practicing a reliable method of contraception, patients with previous treatment with sertraline or fluoxetine, treated with MAOI within two weeks or other antidepressants medication within one week of double‐blind therapy, treated with reserpine or methyl‐dopa, likely to require additional treatments with psychoactive medication, ECT or intensive psychotherapy during the study; failure to respond to previous antidepressant therapy at clinically appropriate dosages, use of ECT to treat a previous episode of depression, a history of severe allergies or multiple adverse events associated with pharmacotherapy, the presence of significant medical disease; psychiatric history including another Axis I disorder and significant suicide risk.
Interventions	Fluoxetine: 144 participants Sertraline: 142 participants Fluoxetine dose range: 20‐40 mg/day Sertraline dose range: 50‐100 mg/day Chloral hydrate (max 1 g) and temazepam (max 20 mg) were allowed as hypnotic
Outcomes	Primary outcome: HDRS‐17, Clinical Global Impression Severity and Improvement Scales (CGI S‐I) Secondary outcomes: Hamilton Rating Scale for Anxiety, the Raskin Depression Scale and Covi Anxiety Scale, self‐rated Leeds Sleep Questionnaire
Notes	Patients with concomitant medical conditions were allowed to participate in the study provided that the conditions were clearly not associated with the illness of the study and that any required medications were not psychoactive agents. One patient attempted suicide in the fluoxetine group. Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly assigned, in equal proportion", no other information
Allocation concealment (selection bias)	Unclear risk	No information
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Low risk	Number and reasons for dropout reported. Scores reported with denominator
Selective reporting (reporting bias)	Unclear risk	Scores reported without standard deviations. Only adverse events occurring at least in 3% of the sample reported
Other bias	High risk	Quote: "supported by a research grant from international Pharmaceuticals group, Pfizer, Inc, New York". This company produces sertraline